Results 1 to 10 of about 34,241 (258)
Development of a new HISCL automated CXCL9 immunoassay
Scientific Reports, 2023 C–X–C motif chemokine ligand 9 (CXCL9), a candidate biomarker, reflects type 1 (T1) inflammation pathology. Here, we report the analytical performance and clinical characteristics of a new CXCL9 reagent for a fully automated immunoassay device.
Takehiro Hasegawa +13 more
doaj +4 more sources
Cell Reports, 2023 Summary: CXCL9 expression is a strong predictor of response to immune checkpoint blockade therapy. Accordingly, we sought to develop therapeutic strategies to enhance the expression of CXCL9 and augment antitumor immunity.
Amanda X Y Chen, Emma V Petley
exaly +6 more sources
CXCL9-Derived Peptides Differentially Inhibit Neutrophil Migration In Vivo through Interference with Glycosaminoglycan Interactions [PDF]
Frontiers in Immunology, 2017 Several acute and chronic inflammatory diseases are driven by accumulation of activated leukocytes due to enhanced chemokine expression. In addition to specific G protein-coupled receptor-dependent signaling, chemokine–glycosaminoglycan (GAG ...
Vincent Vanheule +2 more
exaly +4 more sources
Frontiers in Oncology, 2021 The chemokine CXCL9 (C-X-C motif chemokine ligand 9) has been reported to be required for antitumour immune responses following immune checkpoint blockade. In this study, we sought to investigate the potential value of CXCL9 according to immune responses
Chun-Fa Chen +2 more
exaly +3 more sources
Osteoblasts secrete Cxcl9 to regulate angiogenesis in bone
Nature Communications, 2016 Communication between osteoblasts and endothelial cells (ECs) is essential for bone turnover, but the molecular mechanisms of such communication are not well defined.
Bin Huang +16 more
doaj +3 more sources
Inhibition of renal fibrosis with a human CXCL9‐derived glycosaminoglycan‐binding peptide [PDF]
Clinical & Translational Immunology, 2022 Objectives Renal fibrosis accompanies all chronic kidney disorders, ultimately leading to end‐stage kidney disease and the need for dialysis or even renal replacement.
Fariba Poosti +12 more
doaj +3 more sources
Targeting cellular source-specific CXCL9 signaling for immunotherapy in oral squamous cell carcinoma [PDF]
Frontiers in ImmunologyOral squamous cell carcinoma (OSCC) remains a clinical challenge due to its high recurrence, metastatic potential, and limited responsiveness to current immunotherapies.
Miao Qiu +4 more
doaj +2 more sources
CXCL9: evidence and contradictions for its role in tumor progression
Cancer Medicine, 2016 AbstractChemokines are a group of low molecular weight peptides. Their major function is the recruitment of leukocytes to inflammation sites, but they also play a key role in tumor growth, angiogenesis, and metastasis. In the last few years, accumulated experimental evidence supports that monokine induced by interferon (IFN)‐gamma (CXCL9), a member of ...
Panpan Lu, Yujia Xia, Yuhui Fan
exaly +4 more sources
CT radiomics prediction of CXCL9 expression and survival in ovarian cancer
Journal of Ovarian Research, 2023 Background C-X-C motif chemokine ligand 9 (CXCL9), which is involved in the pathological processes of various human cancers, has become a hot topic in recent years.
Rui Gu +10 more
doaj +3 more sources
Clinical and Translational Medicine, 2017 Background and aims CXCL9-11 polymorphisms are related to various infectious diseases, including hepatitis C virus (HCV) infection. In this study, we analyzed the association between CXCL9-11 polymorphisms and liver fibrosis in HCV-infected patients ...
Maria Angeles Jimenez-Sousa +2 more
exaly +3 more sources